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Percutaneous Repair of Paravalvular Regurgitation: Characteristics and Acute
Outcomes of 40 Patients
Sachin S. Goel1, Amar Krishnaswamy2, E. Murat Tuzcu3, Samir Kapadia2
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Background: Percutaneous repair of periprosthetic paravalvular leak (PVL) is
emerging as a potential therapy in patients that are at high surgical risk. We report our
outcomes with this procedure in patients referred for catheter based repair of peri-
prosthetic paravalvular regurgitation.
Methods: We retrospectively identiﬁed 43 percutaneous PVL closures in 40 patients
performed at our institution between May 2009 and November 2012.
Results: The mean age of patients undergoing percutaneous PVL closure was 70
years, with 98% of patients in NYHA class III or IV heart failure and 63% of patients
having evidence of hemolytic anemia. There was a signiﬁcant burden of co-morbid-
ities with a mean estimated mortality of 10.2% as predicted by the STS score. Majority
(86%) were mitral PVL closures. In 81% of cases antegrade transseptal approach was
used. General anesthesia was used sparingly (4 cases). In 50% of cases, more than 1
device was needed. Amplatzer Vascular Plug II was the most frequently used device.
Percutaneous PVL closure was successful in 91% of patients with residual regurgi-
tation of grade 1+ in 51% patients and 2+ in 95% of patients. Procedural failure
occurred in 4 cases.Reasons for failure included prosthetic valve impingement, failure
to cross the leak and signiﬁcant residual leak despite device. Thirty day mortality was
7.5% (3 patients). A total of 3 patients had surgical valve replacement following
percutaneous PVL closure; of which 2 patients underwent surgery within 30 days
and one patient had surgery after 1.6 years. At a mean follow up of 208 days (range 1-
888 days), all cause mortality was 30%.
Conclusions: Percutaneous PVL closure is a valuable treatment option in patients
with paraprosthetic paravalvular regurgitation at high surgical risk, with good acute
procedural success rates.
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Long-term 25 Years Follow-up of Mitral Valvuloplasty with Single Balloon.
Independent Predictors of Survival and Event Free Survival
Edison C. Peixoto1, Rodrigo T. Peixoto2, Ivana Picone Borges2, Ricardo T. Peixoto3
1Fluminense Federal University, Rio de Janeiro, Brazil, 2Military Police Central
Hospital, Rio de Janeiro, Brazil, 3State Institute of Cardiology, Rio de Janeiro, Brazil
Background: Mitral balloon valvuloplasty (MBV) with single balloon (MBVSB) is
the less expensive technique to perform MBV. The objectives were to evaluate long-
term follow-up (FU) of MBVSB Balt and to determine independent predictors of
survival and event-free survival (EFS).
Methods: From 1987 to 12-31-2013, 526 procedures of MBV were performed,
404 (76.8%) with MBVSB Balt, being 256 procedures with long-term FU. The
balloon diameter was 25 mm in 5 procedures and 30 mm in 251, mean dilatation area
7.020.30 cm2. The FU was 5533 (1 to 198) months. To determine independent
predictors of survival and EFS it was used the multivariate Cox analysis.
Results: Mean age was 38.012.6 (13 to 83) years, being 222 (86.7%) female, 215
(84.0%) in sinus rhythm, echo score (ES) 7.21.5 (4 to 14) points and echo mitral
valve area (MVA) pre-MBVSB 0.930.21 cm2. Mean pre and post-MBV area
(Gorlin) was 0.900.20 and 2.020.37 cm2 (p< 0.001) and success MVA 1,5 cm2
in 241 (94.1%) procedures and mean pulmonary artery pressure pre and post MBV
were 2710 and 207 mmHg. Three (1.2%) patients began the FU with severe mitral
regurgitation (SMR). At the end of the FU 118 (46.1%) patients were in NYHA FC I,
71 (27.7%) in FC II, 53 (20.7%) in FC III, 3 (1.2%) in FC IV and there were 11 deaths
(4.3%), 9 (3,5%) were cardiac death, being 5 during cardiac surgery. There were
17 (8.2%) patients with new SMR at the end of the FU. Twelve (4.7%) patients were
submitted to new MBV, 27 (10.5%) to mitral valve surgery and 70 (26.3%) patients
used no medication at the end of the FU. Independent predictors of survival with
7 variables were: ES 8 (P< 0.002, HR¼0.143), age 50 years old (P¼0.014, HR
0.202) and absence of mitral valve surgery in the FU (P¼0.004, HR 0.170), being
cardiac surgery in fhe FU the 7th variable and with 6 variables independent predictors
were: EE 8 (p< 0.001, HR 0,116) and age 50 years old (P¼0,011, HR¼0,203).
Independent predictors of EFS were: absence of prior comissurotomy (P< 0.002,
HR 0.318), female (P¼0.036, HR 0.466) and MVA post MBV.
Conclusions: MBVSB Balt was efﬁcient with durable results similar to others tech-
niques being less expensive.
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First-in-Human CardiAQ Transcatheter Mitral Valve Implantation via
Transapical Approach
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Background: Many patients with severe symptomatic native mitral valve regurgita-
tion are not candidates for surgical replacement or repair due to high operative risk.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ValvulWhile percutaneous repair therapies such as MitraClip are a viable option for such
patients, many have unfavorable anatomy that precludes treatment. Transcatheter
mitral valve implantation (TMVI) is a novel treatment option. We describe the ﬁrst
in human implantation of the CardiAQ valve via transapical approach.
Methods: An 88-year-old female patient with severe mitral regurgitation secondary to
A1/A2 leaﬂet ﬂail and refractory NYHA class IIIb dyspnoea was referred for treat-
ment. Co-morbidities included prior coronary artery bypass surgery and renal failure.
Left ventricular systolic function was preserved. Following discussion in our heart
team meeting the patient was declined surgery and deemed unsuitable for MitraClip.
TMVI was performed under compassionate use provision.
Results: The 33Fr CardiAQ delivery system was inserted via transapical approach in
the hybrid operating theatre. Using transoesophageal echocardiography guidance,
successful device implantation was achieved with an accurate and stable prosthesis
position and immediate elimination of the mitral regurgitation with only trace para-
valvular leak. Over a follow up period of 1 week the prosthetic valve remained well
functioning as assessed by sequential echocardiography, the patient experienced
signiﬁcant symptomatic improvement and recovery was uneventful.
Conclusions: Our initial experience with transcatheter mitral valve implantation using
the CardiAQ device via transapical approach highlights the feasibility and effective-
ness of this promising therapy in treating severe mitral regurgitation.
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Transesophageal echocardiography guided trans-apical mitral implantation
Robert Moss1, Webb John2, Anson Cheung1, Stefan Verheye3, Shmuel Banai4
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Background: Transcatheter mitral valve implantation is an emerging therapeutic
option for high-risk patients with severe symptomatic mitral regurgitation. The Tiara
is a catheter-based self-expanding mitral bio-prosthesis, speciﬁcally designed to ﬁt the
complex anatomical structure of the mitral apparatus. It is implanted using a trans-
apical approach.. Because transesophageal echocardiography (TEE) provides superb
imaging of the mitral valve in both 2 and 3-D, and has the ability to provide real time
information, TEE is ideally suited both assessing suitability and guiding the implan-
tation of trans-catheter mitral procedures. We describe here the TEE guidance of the
ﬁrst 2 human implantations of the Tiara.
Methods: The ﬁrst 2 cases of Transapical Mitral Valve Implantation (TAMI) of
the Tiara were performed in a 72 year-old male and a 60 years old woman with
severe functional MR. Anatomical suitability for Tiara implantation was conﬁrmed
by transthoracic echo, TEE and CT angiographic assessment prior to implantation.
Implantation was guided by both TEE and ﬂuoroscopy. TEE was critical in deter-
mining the orientation of the “D” shaped Tiara prior to deployment. In particular,
the orientation of the device in the left atrium was conﬁrmed using X-plane
imaging, and rotational orientation by real time 3-D echo. Final deployment position,
paravalvular mitral regurgitation and the presence of any complications was evaluated.
Results: TEE guided Tiara implantation was completed successfully in both patients
and both valves were deployed in an appropriate position and orientation. There were
no complications detected by TEE at the time of implantation. Speciﬁcally no left
ventricular outﬂow tract obstruction, pericardial effusion or deterioration in LV or RV
function was noted. No new wall motion abnormalities were noted. Mitral regurgi-
tation was reduced from 4+ to trivial and trans-mitral gradient was minimal in both
patients.
Conclusions: TEE echo provides critical real time information that is integral to
successful positioning, deployment and assessment of outcomes with trans-catheter
mitral valve implantation.
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Immediate and 18-Month Outcome of Balloon Mitral Valvuloplasty:
Comparison of Inoue and Multi-Track System
Ali Youssef1, Mohamed Oraby1
1Suez Canal University, Ismailia, Egypt
Background: To compare the immediate and 18-month clinical and echocardio-
graphic outcome of Inoue and multi-track system for balloon mitral valvuloplasty
(BMV).
Methods: We included 78 consecutive patients with moderate to severe rheumatic
mitral stenosis (MS) [mitral valve area (MVA)< 1.5 cm2] and clinically indicated
BMV. The ﬁrst 42 consecutive patients were assigned to Inoue BMV (group I), and
the following 36 consecutive patients were assigned to multi-track system (group M).
Clinical and echocardiographic assessment was performed before, immediately after,
3 months after, and 18 months after the procedure.
Results: The successful immediate result [MVA > 1.5 cm2 and mitral regurgitation
(MR) < II/IV] was achieved in 40 (95.23%) patients of group I and 34 (94.44%)
patients of group M (P ¼ 0.12). Immediately after BMV,MVA increased from
0.9  0.4 to 1.7  0.5 cm2 in group I and from 0.8  0.2 to 1.9  0.3 cm2 in group M
(P < 0.01). Bilateral commissural splitting was signiﬁcantly higher in group M
(P < 0.01). This was associated with higher incidence of mild commissural mitral
regurgitation. There were no signiﬁcant differences of moderate to severe MR. Both
procedure and ﬂuoroscopy time were signiﬁcantly shorter in group I (P < 0.001).
Eighteen month clinical and echocardiographic evaluation was available forar disease - Mitral: Transcatheter therapies (non-MitraClip) B237
Table. Mean MR Grade, 6MWD and NYHA through 12 months (p value
compared to baseline)
Baseline 1 month 6 months* 12 months*
Mean MR
Grade
2.73 0.6
(N¼26)
1.57 0.95
(N¼23,
1.35 0.79
(N¼17,
1.13 0.89
(N¼16,
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.com66 (84.64%) patients with sustained immediate clinical and echocardiographic
improvements.
Conclusions: Both Inoue and the multi-track balloon systems achieved successful
immediate and 18-month results. The multi-track double balloon system produced
signiﬁcantly larger MVA, with better bilateral commissurotomy,yet with longer pro-
cedure and ﬂuoroscopy times.p<0.001) p<0.001) p<0.001)
Mean 6MWD
(m)
291.2
82.6
(N¼28)
376.2
100.8
(N¼25,
p<0.001)
419.9
116.3
(N¼14,
p<0.001)
383.8
142.1
(N¼16,
p¼0.002)
Mean NYHA
Class
3.03
0.42
(N¼29)
2.11 0.57
(N¼28,
p<0.001)
2.05 0.71
(N¼19,
p<0.001)
2.06 0.66
(N¼17,
p<0.001)
* Preliminary Data - data collection not completeTCT-814
Mitral Annular Evaluation with Computed Tomography in the Context of
Transcatheter Mitral Valve Implantation: A New Paradigm
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Background: The non-planar, saddle-shaped structure of the mitral annulus has been
well established through decades of anatomical and echocardiographic study. Its
relevance for mitral annular assessment for transcatheter mitral valve implantation
(TMVI) is uncertain. We sought to deﬁne the methodology for computed tomography
(CT)-based “D -shaped’ mitral annular assessment for TMVI and compare these
measurements to traditional “saddle-shaped” mitral annular assessment.
Methods: ECG-gated, end-diastolic CT data of 28 patients with severe functional
mitral regurgitation was analyzed. The annular contour was segmented and ﬁbrous
trigones were identiﬁed yielding annular perimeter, projected area, inter-trigone (TT)
and septal-lateral (SL) distances and annular height. The traditional saddle shaped
annulus was deﬁned including the aortomitral continuity. The D-shaped annulus was
deﬁned as being limited anteriorly by the TT line, excluding the aortomitral conti-
nuity. Hypothetical left ventricular outﬂow tract (LVOT) clearance and orthogonal
projection angles were assessed.
Results: Projected area, perimeter and SL distance were found to be signiﬁcantly
smaller for the D-shaped annulus than for the saddle-shaped annulus (11.22.7cm2
vs. 13.03.0cm2, 124.115.1mm vs. 136.015.5mm, 32.14.0mm vs.
40.14.9mm respectively, p< 0.001). TT distances were identical (32.74.1mm).
The D-shaped annulus was more planar demonstrating a reduced annular height
(2.41.0mm vs. 10.61.8mm, p< 0.001). LVOT clearance was signiﬁcantly
reduced for the saddle-shaped annulus, but preserved for the D-shaped annulus
(10.72.2mm vs. 17.53.0mm, p< 0.001). A line of perpendicularity for orthogonal
views was identiﬁed. SL views were on average found at 25.57.7 RAO,
22.510.2 cranial, whereas TT views were found at 74.720.5 RAO, 57.08.4
caudal.
Conclusions: The historically established methodology for mitral annulus sizing
appears inappropriate for TMVI, yielding signiﬁcantly larger dimensions compared to
the D-shaped annulus approach with resultant signiﬁcantly reduced LVOT clearance.
CT-based mitral annular assessment may aid pre-procedural sizing, ensuring appro-
priate patient and device selection and guide device deployment.TCT-815
Treatment of Functional Mitral Regurgitation by Percutaneous Annuloplasty
Using the Carillon Mitral Contour System Results in Improved Clinical
Efﬁcacy – The TITAN II Study
Michael Haude1, Hubertus Degen2, Tomasz Siminiak3, Piotr Kalmucki3,
Horst Sievert4, Jochen Müller-Ehmsen5, Benjamin Krausgrill5, Janusz Lipiecki6
1Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany, 2Städtische
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Medical Sciences Interventional Cardiology, Poznan, Poland, 4CardioVascular
Center Frankfurt, Frankfurt, Germany, 5Universität zu Köln, Köln, Germany, 6Pôle
Santé République, Clermont Ferrand, France
Background: Functional mitral regurgitation (FMR) contributes to both morbidity
and mortality of patients with systolic heart failure. Percutaneous mitral
annuloplasty (PMA), using the Carillon Mitral Contour System, to reduce FMR is
feasible in these patients. The aim of the study was to assess whether the reduction of
FMR associated with PMA will result in clinical beneﬁt as measured by exercise
capacity.
Methods: Patients with NYHA II-IV heart failure and stable medical therapy, mod-
erate to severe FMR, and LVEF< 40% underwent PMA. Clinical measures of efﬁcacy
including NYHA and six minute walk distance (6MWD) were collected through
12 months.
Results: At baseline, dilated cardiomyopathy was of ischemic origin in 60% of pa-
tients, mean EF was 32.3%, and mean LV end diastolic dimension was 6.4 cm.
Carillon device placement was achieved in 30/36 patients (83%). The major adverse
event rate at 30-days for all 36 attempted patients was 2.8% (one death unrelated to
the procedure or the device). There were no device related major adverse events
through 12 months. The 12-month mortality was 23%. The changes in mean MR
Grade, 6MWD and NYHA classiﬁcation through 12 months are detailed in the table
below.B238 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TConclusions: Implantation of the modiﬁed Carillon device using reﬁned procedural
techniques was safe, resulted in an improved implant rate and reduction in FMR and
was associated with marked symptomatic and functional improvement.TCT-816
Comparison between of Mitral Balloon Valvuloplasty and Surgical
Commissurotomy for Mitral Valve Stenosis: Meta-Analysis of the
Randomized Clinical Trials
Daniel Garcia1, Mohammad M. Ansari2, Claudia A. Martinez3, Alexandre Ferreira1,
Eduardo de Marchena4
1University of Miami, Miami, FL, 2University of Miami- Jackson Memorial Hospital,
Miami, FL, 3University of Miami, Miller School of Medicine, Miami, FL, 4University
of Miami Miller School of Medicine, Miami, FL
Background: Percutaneous mitral valvuloplasty (PMB) has been described as a
feasible alternative option for surgical commissurotomy among patients with
mitral valve stenosis. We aimed to evaluate the post procedures outcomes and
its clinical signiﬁcance on long term follow up between these two treatment
modalities.
Methods: Pub Med, Cochrane and Scopus were systematically searched up to
May 2014. Subjects of analysis were post procedure hemodynamic analysis of mitral
valve area by Gorlin formula and transmitral gradient. Post procedure long
term follow-up outcomes were analyzed by MVA, mitral valve re-stenosis, new or
increase of mitral regurgitation, and poor clinical status as NYHA class III/IV. We
used Fixed or Random Effect analysis using the Cochrane Handbook of Systematic
Reviews.
Results: A total of 9 RCTs were selected and provided a total of 1200 patients on the
PBM group and 1020 patients on the surgical group. The PMB presented with a trend
towards higher MVA with signiﬁcant decrease of the transmitral gradient (Figure 1).
Clinical follow up disclosed no difference among groups (Figure 2).CT Abstracts/Valvular disease - Mitral: Transcatheter therapies (non-MitraClip)
